Peroxisome proliferator-activated receptor gamma 2 (PPAR-γ2)

Peroxisome proliferator-activated receptor gamma 2 (PPAR-γ2) is a nuclear receptor and ligand-activated transcription factor expressed predominantly in adipose tissue and to a lesser extent in the intestine. It is a key regulator of adipogenesis, lipid metabolism, and glucose homeostasis. PPAR-γ2 acts by forming heterodimers with retinoid X receptors, binding to specific DNA response elements and controlling the transcription of genes involved in fat cell development and energy storage. Clinically, it is the primary target of thiazolidinediones—insulin-sensitizing agents approved for type 2 diabetes. PPAR-γ2 also modulates inflammation, immune response (notably via M2 macrophage polarization), and has roles in various diseases, including metabolic syndrome, atherosclerosis, cancer, and inflammatory disorders. Drug development efforts focus on designing PPAR-γ2 partial agonists to retain metabolic benefits while reducing adverse effects caused by full activation[1][2][3][6].

Other names

Peroxisome proliferator-activated receptor gamma (PPAR-γ, PPARG)nuclear receptor subfamily 1 group C member 3 (NR1C3)glitazone reverse insulin resistance receptor

Full agonists: Activate PPAR-γ2 leading to increased adipocyte differentiation, enhanced insulin sensitivity, and changes in gene expression controlling metabolism Partial agonists: Selectively modulate coactivator recruitment and gene activation, with reduced side effects compared to full agonists Antagonists: Inhibit PPAR-γ2–dependent transcriptional activity